|
|
Randomized study with the
pineal hormone melatonin versus supportive care alone in advanced nonsmall cell
lung cancer resistant to a first-line chemotherapy containing cisplatin
Lissoni P, Barni S, Ardizzoia A, Paolorossi F, Crispino S,
Tancini G, Tisi E, Archili C, De Toma D, Pipino G, et al
Division of Radiation Oncology, San Gerardo
Hospital, Monza, Italy
At present, there is no effective medical therapy in metastatic
nonsmall cell (NSC) lung cancer patients who progressed under a first-line
chemotherapy containing cisplatin.
Since recent data have demonstrated the
antineoplastic properties and the lack of toxicity of the pineal hormone
melatonin (MLT), a randomized study was designed to evaluate the influence of an
MLT treatment (10 mg/day orally at 7.00 p.m.) on the survival time at 1 year
from the progression under chemotherapy in respect to supportive care alone in a
group of metastatic NSC lung cancer patients, who did not respond to a
first-line chemotherapy containing cisplatin.
The study includes 63 consecutive
metastatic NSC lung cancer patients, who were randomized to receive MLT (n = 31)
or supportive care alone (n = 32).
The percentage of both stabilizations of
disease and survival at 1 year was significantly higher in patients treated with
MLT than in those treated only with supportive care.
No drug-related toxicity
was seen in patients treated with MLT, who, on the contrary, showed a
significant improvement in performance status.
This randomized study shows that
the pineal hormone MLT may be successfully administered to prolong the survival
time in metastatic NSC lung cancer patients who progressed under a first-line
chemotherapy with cisplatin, for whom no other effective therapy is available up
to now.
PMID: 1382256 [PubMed - indexed for MEDLINE]
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1382256&dopt=Abstract
|
